Btcp Pharma Drug Patent Portfolio
Btcp Pharma owns 2 orange book drugs protected by 16 US patents Given below is the list of Btcp Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9731869 | Container | 26 Jan, 2032 | Active |
| US8486972 | Sublingual fentanyl spray | 27 Apr, 2030 | Active |
| US8486973 | Sublingual fentanyl spray | 27 Apr, 2030 | Active |
| US10016403 | Sublingual fentanyl spray | 25 Jan, 2027 | Active |
| US10610523 | Sublingual fentanyl spray | 25 Jan, 2027 | Active |
| US8835459 | Sublingual fentanyl spray | 25 Jan, 2027 | Active |
| US8835460 | Sublingual fentanyl spray and methods of treating pain | 25 Jan, 2027 | Active |
| US9241935 | Sublingual fentanyl spray | 25 Jan, 2027 | Active |
| US9289387 | Method of treating pain by administering sublingual fentanyl spray | 25 Jan, 2027 | Active |
| US9642797 | Sublingual fentanyl spray and methods of use to treat pain | 25 Jan, 2027 | Active |
| US9642844 | Sublingual fentanyl spray | 25 Jan, 2027 | Active |
| US8216604 | Method of managing or treating pain | 03 Oct, 2024 | Expired |
| US8889176 | Method of managing or treating pain | 16 Jan, 2024 | Expired |
| US9078814 | Intranasal spray device containing pharmaceutical composition | 08 Jan, 2024 | Expired |
| US9814705 | Intranasal spray device containing pharmaceutical composition | 08 Jan, 2024 | Expired |
| US6432440 | Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces | 20 Apr, 2018 | Expired |
Latest Legal Activities on Btcp Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Btcp Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 13 May, 2024 | US10610523 |
|
Expire Patent
Critical
| 29 Apr, 2024 | US9289387 |
|
Maintenance Fee Reminder Mailed
Critical
| 26 Feb, 2024 | US8216604 |
|
Maintenance Fee Reminder Mailed
Critical
| 27 Nov, 2023 | US10610523 |
|
Maintenance Fee Reminder Mailed
Critical
| 13 Nov, 2023 | US9289387 |
|
Expire Patent
Critical
| 21 Aug, 2023 | US9078814 |
|
Maintenance Fee Reminder Mailed
Critical
| 06 Mar, 2023 | US9078814 |
|
Expire Patent
Critical
| 26 Dec, 2022 | US8889176 |
|
Expire Patent
Critical
| 24 Oct, 2022 | US8835460 |
|
Expire Patent
Critical
| 15 Aug, 2022 | US10016403 |
|
Maintenance Fee Reminder Mailed
Critical
| 11 Jul, 2022 | US8889176 |
|
Maintenance Fee Reminder Mailed
Critical
| 10 May, 2022 | US8835460 |
|
Maintenance Fee Reminder Mailed
Critical
| 28 Feb, 2022 | US10016403 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 May, 2021 | US9814705 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2021 | US9731869 |
Btcp Pharma's Drug Patent Litigations
Btcp Pharma's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 24, 2015, against patent number US8835460. The petitioner Coalition For Affordable Drugs XI LLC, challenged the validity of this patent, with Insys Pharma, Inc. as the respondent. Click below to track the latest information on how companies are challenging Btcp Pharma's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8486972 | August, 2015 |
Terminated-Denied
(10 Mar, 2016)
| Insys Pharma, Inc. | Coalition For Affordable Drugs XI LLC |
| US8835459 | August, 2015 |
Terminated-Denied
(10 Mar, 2016)
| Insys Pharma, Inc. | Coalition For Affordable Drugs XI LLC |
| US8835460 | August, 2015 |
Terminated-Denied
(10 Mar, 2016)
| Insys Pharma, Inc. | Coalition For Affordable Drugs XI LLC |
Btcp Pharma Drug Patents' Oppositions Filed in EPO
Btcp Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 18, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP04701381A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP04701381A | Jun, 2014 | Generics [UK] Limited | Opposition rejected |
Btcp Pharma's Family Patents
Btcp Pharma Drug List
Given below is the complete list of Btcp Pharma's drugs and the patents protecting them.
1. Lazanda
Lazanda is protected by 6 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9731869 | Container |
26 Jan, 2032
(7 years from now)
| Active |
| US8216604 | Method of managing or treating pain |
03 Oct, 2024
(2 months ago)
| Expired |
| US8889176 | Method of managing or treating pain |
16 Jan, 2024
(11 months ago)
| Expired |
| US9078814 | Intranasal spray device containing pharmaceutical composition |
08 Jan, 2024
(11 months ago)
| Expired |
| US9814705 | Intranasal spray device containing pharmaceutical composition |
08 Jan, 2024
(11 months ago)
| Expired |
| US6432440 | Pectin compositions and methods of use for improved delivery of drugs to mucosal surfaces |
20 Apr, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lazanda's drug page
2. Subsys
Subsys is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8486972 | Sublingual fentanyl spray |
27 Apr, 2030
(5 years from now)
| Active |
| US8486973 | Sublingual fentanyl spray |
27 Apr, 2030
(5 years from now)
| Active |
| US10016403 | Sublingual fentanyl spray |
25 Jan, 2027
(2 years from now)
| Active |
| US10610523 | Sublingual fentanyl spray |
25 Jan, 2027
(2 years from now)
| Active |
| US8835459 | Sublingual fentanyl spray |
25 Jan, 2027
(2 years from now)
| Active |
| US8835460 | Sublingual fentanyl spray and methods of treating pain |
25 Jan, 2027
(2 years from now)
| Active |
| US9241935 | Sublingual fentanyl spray |
25 Jan, 2027
(2 years from now)
| Active |
| US9289387 | Method of treating pain by administering sublingual fentanyl spray |
25 Jan, 2027
(2 years from now)
| Active |
| US9642797 | Sublingual fentanyl spray and methods of use to treat pain |
25 Jan, 2027
(2 years from now)
| Active |
| US9642844 | Sublingual fentanyl spray |
25 Jan, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Subsys's drug page